Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea

Yong Park, MD, Dae Sik Kim, MD PhD, Ka-Won Kang, MD, Byung-Hyun Lee, MD, Eun Sang Yu, MD, Min Ji Jeon, MD, Hojoon Choi, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Kihyun Kim, MD PhD, Byung Soo Kim, MD PhD, Seok Jin Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2018-99-115625

Published: 2018

Journal Articles

Immature Platelet Fraction Based Diagnostic Predictive Model for Immune Thrombocytopenic Purpura

Min Ji Jeon, MD, Hojoon Choi, MD, Eun Sang Yu, MD, Ka-Won Kang, MD, Byung-Hyun Lee, MD, Dae Sik Kim, MD PhD, Yong Park, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2018) 132 (Supplement 1): 1149.

https://doi.org/10.1182/blood-2018-99-117754

Published: 2018

Journal Articles

The Potential of Exosomes Derived from Chronic Myelogenous Leukemia Cells As Biomarker Based on the BCR-ABL mRNA Transcript

Ka-Won Kang, MD, Jik-han Jung, Woojune Hur, Jaena Park, Hyunku Shin, ByeongHyeon Choi, Hyesun Jeong, Dae Sik Kim, MD PhD, Eun Sang Yu, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Seok Jin Kim, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD, Hyun Koo Kim, MD PhD, Sunghoi Hong, PhD, Ji-ho Park, PhD, Yeonho Choi, PhD, Yong Park, MD PhD

Blood (2017) 130 (Supplement 1): 2883.

https://doi.org/10.1182/blood.V130.Suppl_1.2883.2883

Published: 2017

Journal Articles

Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies

Ka-Won Kang, MD, Yong Park, MD PhD, Dae Sik Kim, MD PhD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Seok Jin Kim, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2015) 126 (23): 4889.

https://doi.org/10.1182/blood.V126.23.4889.4889

Published: 2015

Journal Articles

High-Dose Cytarabine Alone Versus Cytarabine Plus Anthracycline for Consolidation Therapy in Non-Promyelocytic Acute Myeloid Leukemia

Sung-Hyun Kim, So Yeon Kim, Ji Hyun Lee, MD PhD, Suee Lee, Sung Yong Oh, Hyo-Jin Kim, Dae Sik Kim, MD, Ka-Won Kang, MD, Se Ryeon Lee, MD PhD, Yong Park, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2015) 126 (23): 4890.

https://doi.org/10.1182/blood.V126.23.4890.4890

Published: 2015

Journal Articles

Efficacy Of Ruxolitinib In Korean Myelofibrosis Patients and Cases Complicated TB Lymphadenitis During The Treatment

Yeo-Kyeoung Kim, MD, PhD, Se Ryeon Lee, MD, PhD, Yong Park, MD, PhD, Chul Won Choi, MD, PhD, Soo Jeong Kim, MD, PhD, Ho-Young Yhim, MD, PhD, Inho Kim, Doyeun Oh, MD, PhD, Yeung-Chul Mun, Sung-Nam Lim, MD, PhD, Jeong-A Kim, PhD, MD, Myung-Geun Shin, MD, PhD, Jong-Ho Won, MD, PhD

Blood (2013) 122 (21): 1596.

https://doi.org/10.1182/blood.V122.21.1596.1596

Published: 2013

Journal Articles

High-Dose Cytarabine Consolidation (≥1.5 g/m 2 ) Might Have Shown a Better Outcomes Than Intermediate-Dose Cytarabine (1.0 g/m 2 ) Combined With Anthracyclines In AML Patients Who Had Achieved Complete Remissions In The First Induction by Standard 3+7 Regimen

Yong Park, MD, PhD, Ga-won Kang, MD, Dae Sik Kim, MD, Suk-young Lee, MD, Ph.D, Se Ryeon Lee, MD, PhD, Hwa Jung Sung, Chul Won Choi, MD, PhD, Seok Jin Kim, MD, PhD, Myunghyun Nam, MD, PhD, Ji-Seon Choi, MD, PhD, Soo-Young Yoon, MD, PhD, Byung Soo Kim, Insun Kim, MD, PhD

Blood (2013) 122 (21): 2692.

https://doi.org/10.1182/blood.V122.21.2692.2692

Published: 2013

Journal Articles

Sustained Long-Term MMR to a Reduced Dose of Imatinib in Chronic-Phase CML: A Pilot Study of SLC22A1 Gene Polymorphisms

Se Ryeon Lee, MD, PhD, Seok Young Lee, MD, Dae Sik Kim, MD, Yong Park, MD, Hwa Jung Sung, Chul Won Choi, MD, Jae Sook Ahn, MD, Deok-Hwan Yang, MD, PhD, Byung Soo Kim, MD, PhD

Blood (2012) 120 (21): 4449.

https://doi.org/10.1182/blood.V120.21.4449.4449

Published: 2012

Journal Articles

Relapse Pattern After Bortezomib Based Salvage Therapy in Patients with Multiple Myeloma

Jae-Sook Ahn, MD, PhD, Deok-Hwan Yang, MD, PhD, Sung-Hoon Jung, MD, Se Ryeon Lee, MD, PhD, Yeo-Kyeoung Kim, MD, PhD, Hyeoung-Joon Kim, MD, PhD, Je-Jung Lee, MD, PhD

Blood (2012) 120 (21): 1869.

https://doi.org/10.1182/blood.V120.21.1869.1869

Published: 2012

Journal Articles

Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis

Blood (2011) 118 (21): 2044.

https://doi.org/10.1182/blood.V118.21.2044.2044

Published: 2011

Journal Articles

Frontline Autologous Stem Cell Transplantation As Intensive Consolidation in Patients with Peripheral T Cell Lymphomas: Multicenter Phase II Trial in Korea

Jae-Sook Ahn, MD, PhD, Deok-Hwan Yang, MD, PhD, Yee Soo Chae, MD, PhD, Sang Kyun Sohn, MD, PhD, Jae-Yong Kwak, MD, PhD, Ho-Young Yhim, MD, PhD, Se-Ryeon Lee, MD, PhD, Sung-Hoon Jung, MD, Soo-Young Bae, MD, Yeo-Kyeoung Kim, MD, PhD, Hyeoung-Joon Kim, MD, PhD, Je-Jung Lee, MD, PhD

Blood (2011) 118 (21): 4477.

https://doi.org/10.1182/blood.V118.21.4477.4477

Published: 2011

Journal Articles

Bilateral Optic Nerve Invasion of Extranodal Marginal Zone B Cell Lymphoma with Leukemic Subtype

Hwa Jung Sung, MD, PhD, Eui Bae Kim, MD, Se Ryeon Lee, MD, PhD, Kyong Hwa Park, MD, PhD, In Keun Choi, MD, PhD, Sang Chul Oh, MD, PhD, Byung Soo Kim, MD, PhD, Yeul Hong Kim, MD, PhD, Jun Suk Kim, MD, PhD, Hee Yun Seo, MD, Sun Hyung Kim, MD, Soo-Young Yoon, MD, PhD

Blood (2008) 112 (11): 5285.

https://doi.org/10.1182/blood.V112.11.5285.5285

Published: 2008

Journal Articles

Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia : Single-Center Experience

Hwa Jung Sung, MD, PhD, Eui Bae Kim, MD, Se Ryeon Lee, MD, PhD, Hee Yun Seo, MD, Kyong Hwa Park, MD, PhD, In keun Choi, MD, PhD, Sang Chul Oh, MD, PhD, Chul Won Choi, MD, PhD, Byung Soo Kim, MD, PhD, Yeul Hong Kim, MD, PhD, Jun Suk Kim, MD, PhD

Blood (2008) 112 (11): 4007.

https://doi.org/10.1182/blood.V112.11.4007.4007

Published: 2008

NARROW

One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea

Immature Platelet Fraction Based Diagnostic Predictive Model for Immune Thrombocytopenic Purpura

The Potential of Exosomes Derived from Chronic Myelogenous Leukemia Cells As Biomarker Based on the BCR-ABL mRNA Transcript

Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies

High-Dose Cytarabine Alone Versus Cytarabine Plus Anthracycline for Consolidation Therapy in Non-Promyelocytic Acute Myeloid Leukemia

Efficacy Of Ruxolitinib In Korean Myelofibrosis Patients and Cases Complicated TB Lymphadenitis During The Treatment

High-Dose Cytarabine Consolidation (≥1.5 g/m 2 ) Might Have Shown a Better Outcomes Than Intermediate-Dose Cytarabine (1.0 g/m 2 ) Combined With Anthracyclines In AML Patients Who Had Achieved Complete Remissions In The First Induction by Standard 3+7 Regimen

Sustained Long-Term MMR to a Reduced Dose of Imatinib in Chronic-Phase CML: A Pilot Study of SLC22A1 Gene Polymorphisms

Relapse Pattern After Bortezomib Based Salvage Therapy in Patients with Multiple Myeloma

Frontline Autologous Stem Cell Transplantation As Intensive Consolidation in Patients with Peripheral T Cell Lymphomas: Multicenter Phase II Trial in Korea

Bilateral Optic Nerve Invasion of Extranodal Marginal Zone B Cell Lymphoma with Leukemic Subtype

Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia : Single-Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only